PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 11, 2013New England Journal of Medicine2,266 citationsOpen Access

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

View Full Paper
JDJean‐Yves DouillardKOKelly S. OlinerSSSalvatore Siena

Key Points

Key points are not available for this paper at this time.

Abstract

Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Douillard et al. (2013) studied this question.

synapsesocial.com/papers/69d78ccc6cc86f5f11b8a383https://doi.org/10.1056/nejmoa1305275
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer2013 · 249 citations
  2. 2The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients2010 · 265 citations
  3. 3Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer2009 · 227 citations
  4. 4Surveyor TM nuclease-based detection of p53 gene mutations in haematological malignancy2007 · 30 citations
  5. 5TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck2007 · 834 citations